Halozyme Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,397	1,015	829.25	660.12	443.31
Revenue Growth (YoY)	37.55%	22.44%	25.62%	48.91%	65.66%
Cost of Revenue	310.26	238.47	268.72	205.91	117.09
Gross Profit	1,086	776.86	560.53	454.21	326.23
Selling, General & Admin	193.39	154.34	149.18	121.63	50.32
Amortization of Goodwill & Intangibles	76.66	71.05	73.77	43.15	-
Operating Expenses	270.05	225.38	222.96	164.77	50.32
Operating Income	816.29	551.48	337.57	289.43	275.9
Interest Expense	-18.13	-18.1	-18.76	-16.95	-7.53
Interest & Investment Income	18.01	12.83	10	3.88	3.36
EBT Excluding Unusual Items	816.17	546.21	328.81	276.36	271.74
Merger & Restructuring Charges	-13.7	-	-	-21.9	-
Gain (Loss) on Sale of Investments	3.47	10.93	6.32	-2.83	-2.26
Asset Writedown	-48.7	-	-	-	-
Other Unusual Items	-5.48	-	13.2	-2.71	-20.96
Pretax Income	466.88	557.13	348.33	248.92	248.52
Income Tax Expense	149.99	113.04	66.74	46.79	-154.19
Net Income	316.89	444.09	281.59	202.13	402.71
Net Income to Common	316.89	444.09	281.59	202.13	402.71
Net Income Growth	-28.64%	57.71%	39.31%	-49.81%	211.97%
Shares Outstanding (Basic)	120	127	132	137	141
Shares Outstanding (Diluted)	124	129	134	141	147
Shares Change (YoY)	-4.26%	-3.56%	-4.56%	-4.21%	3.77%
EPS (Basic)	2.64	3.50	2.13	1.48	2.86
EPS (Diluted)	2.56	3.43	2.10	1.44	2.74
EPS Growth	-25.36%	63.33%	45.83%	-47.45%	201.10%
Free Cash Flow	644.59	468.37	373.28	235.3	297.98
Free Cash Flow Per Share	5.20	3.62	2.78	1.67	2.03
Gross Margin	77.78%	76.51%	67.59%	68.81%	73.59%
Operating Margin	58.45%	54.32%	40.71%	43.84%	62.24%
Profit Margin	22.69%	43.74%	33.96%	30.62%	90.84%
Free Cash Flow Margin	46.15%	46.13%	45.01%	35.64%	67.22%
EBITDA	897.84	627.09	416.93	336.07	277.3
EBITDA Margin	64.29%	61.76%	50.28%	50.91%	62.55%
D&A For EBITDA	81.55	75.61	79.36	46.64	1.4
EBIT	816.29	551.48	337.57	289.43	275.9
EBIT Margin	58.45%	54.32%	40.71%	43.84%	62.24%
Effective Tax Rate	32.13%	20.29%	19.16%	18.80%	-
Revenue as Reported	1,397	1,015	829.25	660.12	443.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.